PEDPOC
PreEclampsia Diagnostics at the Point Of Care
Rapid diagnosis of preeclampsia at the point-of-care
MOMM Diagnostics conceives a new generation of in-vitro diagnostic tests for early diagnosis of preeclampsia. Preeclampsia remains to this day one of the leading causes for maternal mortality. Early diagnosis is therefore vital to minimize complications and prepare adequately for birth. The project partners are developing a solution using microscale solid-state sensors for electrical detection of biomarkers in blood, which will allow the detection of multiple biomarkers, using a single-use cartridge and a hand-held reader for diagnosis of the condition directly where the patients are being taken care of. Technology originating from results of the FETOPEN project RECORD-IT (Project ID: 664786) has shown promising innovation potential. MOMM Diagnostics aims to verify this potential for commercialization by assessing its competitiveness for point of care applications. The technology promises an increased signal to noise ratio at a smaller form factor and lower cost compared to commercially available technologies.
Preeclampsia:
Preeclampsia (PE), one of the most common pregnancy complications, can cause severe threats to mother and baby. Early diagnosis of the condition is of utmost importance for optimal patient care to minimize complications and to save lives. Recent scientific studies have identified biomarkers for the prediction and diagnosis of PE. While testing for these PE biomarkers becomes available in centralized labs, no POCT solution yet exists on the market. Available POCT technologies don’t offer the detection limit needed for accurate quantification of PE biomarkers.
More information on PE:
Project Partners:
Contact:
https://cordis.europa.eu/project/rcn/222995/factsheet/en